APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
See APC spectral data
Cat # Size Price Quantity Avail. Save
505809 25 µg $40
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg $120
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  2. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  3. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  4. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  5. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  6. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  7. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  8. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  9. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  10. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  11. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  12. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  13. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  14. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  15. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  16. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  17. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  18. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  19. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  20. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  21. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  22. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  23. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  24. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  25. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  26. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  27. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  28. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  29. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  30. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  31. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  32. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  33. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  34. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  35. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  36. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  37. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  38. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  39. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  40. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  41. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  42. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  43. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  44. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  45. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  46. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  47. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  48. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  49. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  50. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  51. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  52. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  53. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  54. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  55. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  56. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  57. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  58. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  59. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  60. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  61. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  62. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  63. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  64. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  65. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  66. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  67. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  68. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  69. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  70. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  71. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  72. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  73. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  74. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  75. Harty J 2009. Infect Immun. 77:1894. PubMed
  76. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  77. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  78. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  79. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  80. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  81. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  82. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  83. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  84. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  85. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  86. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  87. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  88. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  89. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  90. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  91. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  92. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  93. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  94. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  95. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  96. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  97. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  98. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  99. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  100. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  101. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  102. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  103. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  104. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  105. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  106. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  107. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  108. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  109. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  110. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  111. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  112. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  113. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  114. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  115. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  116. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  117. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  118. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  119. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  120. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  121. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  122. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  123. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  124. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  125. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  126. Sheng J, et al. 2021. eLife. 10:00. PubMed
  127. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  128. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  129. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  130. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  131. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  132. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  133. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  134. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  135. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  136. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  137. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  138. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  139. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  140. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  141. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  142. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account